See more : Santacruz Silver Mining Ltd. (0R20.L) Income Statement Analysis – Financial Results
Complete financial analysis of Ocean Biomedical, Inc. (OCEA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocean Biomedical, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Syncro Group AB ser. B (SYNC-B.ST) Income Statement Analysis – Financial Results
- CLIP Corporation (4705.T) Income Statement Analysis – Financial Results
- Innovation Beverage Group Limited (IBG) Income Statement Analysis – Financial Results
- ST Energy Transition I Ltd. (STET-WT) Income Statement Analysis – Financial Results
- Modern Healthcare Technology Holdings Limited (0919.HK) Income Statement Analysis – Financial Results
Ocean Biomedical, Inc. (OCEA)
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 33.93M | 49.00K | 35.00K |
| General & Administrative | 0.00 | 28.41M | 1.60M | 197.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.48M | 28.41M | 1.60M | 197.00K |
| Other Expenses | 0.00 | 1.00K | -1.00K | 0.00 |
| Operating Expenses | 2.48M | 62.35M | 1.65M | 232.00K |
| Cost & Expenses | 2.48M | 62.35M | 1.65M | 232.00K |
| Interest Income | 1.52M | 2.45K | 0.00 | 0.00 |
| Interest Expense | 691.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.52M | 236.56K | 206.30K | 171.86K |
| EBITDA | -957.74K | -564.11K | -1.65M | -232.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.48M | -62.35M | -1.65M | -232.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.52M | 61.78M | -1.00K | 0.00 |
| Income Before Tax | -958.43K | -62.34M | -1.65M | -232.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -236.56K | -206.30K | -171.86K |
| Net Income | 565.47K | -62.34M | -1.65M | -232.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -4.71 | -0.08 | -0.01 |
| EPS Diluted | -0.03 | -4.71 | -0.08 | -0.01 |
| Weighted Avg Shares Out | 36.50M | 13.23M | 20.20M | 20.20M |
| Weighted Avg Shares Out (Dil) | 36.50M | 13.23M | 20.20M | 20.20M |
3 Top Penny Stocks To Watch With Big News Today
Source: https://incomestatements.info
Category: Stock Reports